Poshuvet Tablet 5 mg (Dapagliflozin Propanediol Monohydrate)

Adult dose

The recommended dosage of this medication is 10 mg once daily for both monotherapy and adjunct therapy. In initial combination therapy, it can be administered at 5 mg or 10 mg once daily with metformin. For patients with chronic heart failure and chronic kidney disease, 10 mg once daily is recommended. For patients with severe hepatic impairment, the starting dose is 5 mg, which may be increased to 10 mg if well tolerated. The method of administration is

Child dose

The efficacy and safety of dapagliflozin for children under 18 years of age have not been established; therefore, it is not administered.

This medication should not be used by individuals with allergies to this medication's active ingredients or additives. Patients with type 1 diabetes or diabetic ketoacidosis should also not use this medicament. Patients with genetic lactose intolerance, such as galactose intolerance or Lapp lactase deficiency, and glucose-galactose malabsorption should not take this medication. Patients on dialysis should not use this medication. Caution should be exercised when using this medication in patients with reduced fluid volume or poor kidney function. This medication may lower blood pressure or reduce blood volume; thus, symptomatic hypotension or changes in kidney function may occur, requiring careful monitoring of fluid volume and kidney function before and during administration. Particularly, in patients with moderate to severe reduction in kidney function, blood sugar control effectiveness may decrease, and it is not recommended for patients with very low kidney function. While taking this medication, genital infections or urinary tract infections may occur; thus, immediate treatment should be sought if symptoms arise. When used with drugs that pose a risk of hypoglycemia, hypoglycemic symptoms may occur, necessitating adjustments to the doses of insulin or sulfonylureas. If symptoms of dehydration or hypotension occur due to reduced fluid volume, consultation with healthcare providers is necessary, and the use of this medication may need to be temporarily discontinued if necessary. This medication can cause a serious metabolic disturbance known as diabetic ketoacidosis; seek medical attention immediately if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing occur. Women who are pregnant or breastfeeding are advised not to use this medication, and if pregnancy is confirmed, administration should be stopped. Elderly patients or patients with reduced kidney function require special caution and should undergo regular kidney function testing during the use of this medication. This medication does not significantly impair the ability to operate vehicles or machinery, but caution is needed when taken with medications that pose a risk of hypoglycemia. Finally, this medication should be kept out of reach of children and stored in its original container to maintain quality.

Serious side effects

• Urticaria, severe swelling (edema), diaphoresis,
• chest tightness,
• difficulty breathing,
• profound lethargy,
• sudden and severe headache,
• confusion,
• paralysis,
• generalized severe edema associated with elevated blood pressure,
• diabetic ketoacidosis,
• acute kidney injury,

Mild side effects

• Vulvovaginitis
• balanitis and related genital infections
• urinary tract infections
• fungal infections
• hypoglycemia
• thirst
• dizziness
• constipation
• dry mouth
• back pain

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and kept at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy over time.

Appearance

Yellow, double convex, round film-coated tablet

Package unit

28 tablets (14 tablets/PTP × 2)